阿德福韦酯对乙型肝炎病毒e抗原阴性慢性乙型肝炎患者T细胞亚群的影响_West China Medical Journal

Authors：

 赵川 , 李毅 , 舒丽 , 王文平 , 谭敏 , 杨凤 , 周红

遂宁市中心医院感染科（四川遂宁 629000）;

Corresponding author：

Keywords：

阿德福韦酯; 慢性乙型肝炎; T细胞亚群

DOI：

10.7507/1002-0179.20160028

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探讨阿德福韦酯对乙型肝炎病毒e抗原（HBeAg）阴性慢性乙型肝炎患者外周血T细胞亚群的影响。方法对2012年5月-2013年5月56例慢性乙型肝炎患者常规给予护肝治疗，同时给予口服阿德福韦酯10 mg，1次/d，疗程48周。检测服药前及48周后肝功能、乙型肝炎病毒（HBV） DNA及T细胞亚群。结果经口服阿德福韦酯治疗48周后，患者血清HBV-DNA滴度较治疗前明显下降，肝功能明显改善，CD4⁺T淋巴细胞百分比（37.3%）较治疗前（32.8%）明显升高（P＜0.001），CD4⁺/CD8⁺（1.37）较治疗前（1.11）升高（P＜0.005）。结论阿德福韦酯治疗HBeAg阴性慢性乙型肝炎，在抑制HBV的复制、减轻肝脏炎症反应的同时，也可能改善了慢性乙型肝炎患者的细胞免疫功能。

Citation： 赵川, 李毅, 舒丽, 王文平, 谭敏, 杨凤, 周红. 阿德福韦酯对乙型肝炎病毒e抗原阴性慢性乙型肝炎患者T细胞亚群的影响. West China Medical Journal, 2016, 31(1): 106-108. doi: 10.7507/1002-0179.20160028 Copy

1.	Nan XP, Zhang Y, Yu HT, et al. Circulating CD4⁺CD25^high regulatory T cells and expression of PD-1 and BTLA on CD4⁺ T cells in patients with chronic hepatitis B virus infection[J]. Viral Immunol, 2010, 23(1):63-70.
2.	Ishikawa T. Clinical features of hepatitis B virus-related hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(20):2463-2467.
3.	中华医学会肝病学分会, 中华医学会感染病分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中华肝脏病杂志, 2011, 19(1):13-24.
4.	Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection[J]. Nat Rev Immunol, 2005, 5(3): 215-229.
5.	Shrivastava S, Trehanpati N, Patra S, et al. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns[J]. J Viral Hepat, 2013, 20(8):582-591.
6.	Xu HT, Ye J, Chen YB, et al. Changes in the proportions of CD4(+)T cell subsets defined by CD127 and CD25 expression during HBV infection[J]. Immunol Invest, 2012, 41(3):290-303.
7.	Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol, 2007, 81(8):4215-4225.
8.	赵彩彦, 刘振中, 李静, 等. 慢性乙型肝炎患者应用拉米夫定前后T淋巴细胞亚群、CD4+CD25+调节性T淋巴细胞及白细胞介素-10、干扰素-γ的变化[J]. 中华传染病杂志, 2011, 29(8):480-485.
9.	Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003, 125(6):1714-1722.
10.	Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008,48(3):750-8.
11.	Cooksley H, Chokshi S, Maayan Y, et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4⁺T-cell reactivity[J]. Antimicrob Agents Chemother, 2008, 52(1):312-320.

1. Nan XP, Zhang Y, Yu HT, et al. Circulating CD4⁺CD25^high regulatory T cells and expression of PD-1 and BTLA on CD4⁺ T cells in patients with chronic hepatitis B virus infection[J]. Viral Immunol, 2010, 23(1):63-70.
2. Ishikawa T. Clinical features of hepatitis B virus-related hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(20):2463-2467.
3. 中华医学会肝病学分会, 中华医学会感染病分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中华肝脏病杂志, 2011, 19(1):13-24.
4. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection[J]. Nat Rev Immunol, 2005, 5(3): 215-229.
5. Shrivastava S, Trehanpati N, Patra S, et al. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns[J]. J Viral Hepat, 2013, 20(8):582-591.
6. Xu HT, Ye J, Chen YB, et al. Changes in the proportions of CD4(+)T cell subsets defined by CD127 and CD25 expression during HBV infection[J]. Immunol Invest, 2012, 41(3):290-303.
7. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol, 2007, 81(8):4215-4225.
8. 赵彩彦, 刘振中, 李静, 等. 慢性乙型肝炎患者应用拉米夫定前后T淋巴细胞亚群、CD4+CD25+调节性T淋巴细胞及白细胞介素-10、干扰素-γ的变化[J]. 中华传染病杂志, 2011, 29(8):480-485.
9. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003, 125(6):1714-1722.
10. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008,48(3):750-8.
11. Cooksley H, Chokshi S, Maayan Y, et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4⁺T-cell reactivity[J]. Antimicrob Agents Chemother, 2008, 52(1):312-320.

Previous Article
胸腔积液及高脂血症对重症急性胰腺炎发生的预测作用
Next Article
湿性疗法对乳腺癌根治术后皮瓣坏死的治疗效果

West China Medical Journal

阿德福韦酯对乙型肝炎病毒e抗原阴性慢性乙型肝炎患者T细胞亚群的影响

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content